Avanza Fonder AB Takes $1.39 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Avanza Fonder AB purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 33,504 shares of the company's stock, valued at approximately $1,393,000.

Several other hedge funds have also made changes to their positions in MRNA. Assenagon Asset Management S.A. boosted its position in shares of Moderna by 13.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 14,978 shares of the company's stock worth $623,000 after acquiring an additional 1,819 shares during the last quarter. 180 Wealth Advisors LLC raised its stake in Moderna by 3.2% during the fourth quarter. 180 Wealth Advisors LLC now owns 18,557 shares of the company's stock worth $772,000 after purchasing an additional 578 shares during the period. Green Alpha Advisors LLC boosted its holdings in shares of Moderna by 54.9% in the 4th quarter. Green Alpha Advisors LLC now owns 16,900 shares of the company's stock valued at $703,000 after purchasing an additional 5,987 shares during the last quarter. Czech National Bank increased its holdings in shares of Moderna by 6.6% during the 4th quarter. Czech National Bank now owns 73,424 shares of the company's stock worth $3,053,000 after buying an additional 4,526 shares during the last quarter. Finally, Douglas Lane & Associates LLC increased its holdings in shares of Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company's stock worth $32,175,000 after buying an additional 298,715 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Up 0.9 %

MRNA traded up $0.30 during trading on Friday, hitting $34.06. The company had a trading volume of 7,919,673 shares, compared to its average volume of 7,794,547. Moderna, Inc. has a 1-year low of $31.94 and a 1-year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market cap of $13.11 billion, a PE ratio of -5.85 and a beta of 1.60. The business has a 50-day moving average of $40.85 and a 200-day moving average of $66.05.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company's revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.39) EPS. As a group, analysts forecast that Moderna, Inc. will post -9.3 earnings per share for the current year.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last quarter. Insiders own 15.20% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wolfe Research began coverage on Moderna in a research report on Friday, November 15th. They set an "underperform" rating and a $40.00 price target for the company. Barclays decreased their target price on Moderna from $125.00 to $111.00 and set an "overweight" rating for the company in a report on Friday, November 8th. Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a report on Thursday. HSBC upgraded shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price objective for the company in a research note on Monday, November 18th. Finally, Morgan Stanley cut their target price on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Wednesday. Four investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $75.58.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.